Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
Platzbecker U, Adès L, Montesinos P, Ammatuna E, Fenaux P, Baldus C, Bernardi M, Berthon C, Bocchia M, Bonmati C, Borlenghi E, Bornhäuser M, Carp D, Chantepie S, Crea E, Divona M, Döhner H, Ehninger G, Esteve Reyner J, Frayfer J, Garrido Diaz A, Gil C, Guarnera L, Hamm AF, Heiblig M, Heidenreich D, Krämer AJ, Ledoux MP, Lunghi M, Mancini V, Metzeler K, Miggiano MC, Müller-Tidow C, Peterlin P, Piciocchi A, Rieger K, Röllig C, Rossi G, Sanz MA, Serve H, Söhne M, Spiekermann K, Tavernier-Tardy E, Thiede C, Vives Polo S, Vogel W, Zappasodi P, Ziller-Walter P, Voso MT; SAL, AMCL-CG, AML-SG, OSHO, PETHEMA, HOVON and GIMEMA study groups.
Platzbecker U, et al.
J Clin Oncol. 2025 Oct 10;43(29):3160-3169. doi: 10.1200/JCO-25-00535. Epub 2025 Aug 18.
J Clin Oncol. 2025.
PMID: 40825164
Clinical Trial.
The study was discontinued prematurely because of slow accrual during the COVID-19 pandemic. After a median follow-up of 37 months (range, 1.7-88.6 months), 2-year EFS was 88% in the ATRA-ATO arm and 71% in the ATRA-CHT arm (HR, 0.4 [95% CI, 0.17 to 0.92]; log-rank …
The study was discontinued prematurely because of slow accrual during the COVID-19 pandemic. After a median follow-up of 37 mo …